Arcus Biosciences IncNYSE:RCUS
- LAST PRICE15.3900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots15.3700/ 3
- Ask / Lots15.4000/ 4
- Open / Previous Close15.6900 / 15.3900
- Day Range
- 52 Week Range
- Volume90,042
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RCUS |
|---|---|---|
| 09:32 ET | 2364 | 15.585 |
| 09:38 ET | 1916 | 15.595 |
| 09:41 ET | 1304 | 15.6185 |
| 09:43 ET | 235 | 15.61 |
| 09:45 ET | 1207 | 15.625 |
| 09:48 ET | 100 | 15.67 |
| 09:50 ET | 300 | 15.67 |
| 09:52 ET | 505 | 15.65 |
| 09:54 ET | 300 | 15.63 |
| 09:56 ET | 1729 | 15.67 |
| 09:57 ET | 305 | 15.64 |
| 09:59 ET | 200 | 15.63 |
| 10:01 ET | 1108 | 15.615 |
| 10:03 ET | 300 | 15.68 |
| 10:08 ET | 100 | 15.62 |
| 10:10 ET | 300 | 15.64 |
| 10:12 ET | 300 | 15.66 |
| 10:14 ET | 300 | 15.635 |
| 10:15 ET | 300 | 15.615 |
| 10:17 ET | 200 | 15.6 |
| 10:19 ET | 100 | 15.63 |
| 10:21 ET | 400 | 15.63 |
| 10:24 ET | 803 | 15.64 |
| 10:26 ET | 1449 | 15.67 |
| 10:28 ET | 100 | 15.68 |
| 10:30 ET | 1927 | 15.67 |
| 10:32 ET | 676 | 15.665 |
| 10:33 ET | 100 | 15.61 |
| 10:35 ET | 448 | 15.63 |
| 10:37 ET | 870 | 15.63 |
| 10:39 ET | 108 | 15.64 |
| 10:42 ET | 850 | 15.65 |
| 10:44 ET | 407 | 15.7 |
| 10:46 ET | 357 | 15.72 |
| 10:48 ET | 744 | 15.72 |
| 10:50 ET | 300 | 15.72 |
| 10:51 ET | 441 | 15.69 |
| 10:53 ET | 701 | 15.67 |
| 10:55 ET | 300 | 15.66 |
| 10:57 ET | 600 | 15.63 |
| 11:00 ET | 100 | 15.66 |
| 11:02 ET | 310 | 15.68 |
| 11:06 ET | 100 | 15.67 |
| 11:08 ET | 300 | 15.65 |
| 11:09 ET | 1004 | 15.615 |
| 11:11 ET | 5491 | 15.57 |
| 11:18 ET | 1991 | 15.6 |
| 11:20 ET | 152 | 15.59 |
| 11:22 ET | 1552 | 15.59 |
| 11:24 ET | 100 | 15.58 |
| 11:26 ET | 200 | 15.59 |
| 11:27 ET | 400 | 15.54 |
| 11:29 ET | 200 | 15.56 |
| 11:31 ET | 200 | 15.57 |
| 11:33 ET | 1209 | 15.585 |
| 11:36 ET | 603 | 15.6 |
| 11:38 ET | 1877 | 15.56 |
| 11:40 ET | 942 | 15.52 |
| 11:42 ET | 400 | 15.51 |
| 11:44 ET | 523 | 15.53 |
| 11:47 ET | 400 | 15.53 |
| 11:49 ET | 225 | 15.51 |
| 11:51 ET | 100 | 15.52 |
| 11:58 ET | 442 | 15.56 |
| 12:02 ET | 100 | 15.54 |
| 12:03 ET | 399 | 15.56 |
| 12:05 ET | 950 | 15.55 |
| 12:07 ET | 300 | 15.53 |
| 12:09 ET | 200 | 15.52 |
| 12:12 ET | 300 | 15.5 |
| 12:16 ET | 1658 | 15.45 |
| 12:20 ET | 715 | 15.45 |
| 12:25 ET | 425 | 15.43 |
| 12:27 ET | 400 | 15.43 |
| 12:32 ET | 758 | 15.42 |
| 12:34 ET | 200 | 15.43 |
| 12:36 ET | 1897 | 15.42 |
| 12:39 ET | 6067 | 15.42 |
| 12:41 ET | 536 | 15.39 |
| 12:43 ET | 303 | 15.38 |
| 12:45 ET | 500 | 15.38 |
| 12:50 ET | 200 | 15.38 |
| 12:52 ET | 200 | 15.365 |
| 12:57 ET | 100 | 15.39 |
| 01:01 ET | 100 | 15.39 |
Sep 24, 2024
Arcus Biosciences Announces New Employment Inducement Grants, from 4:35PM ET on Tuesday Sep 24, 2024 by Dow Jones
4:35PM ET on Tuesday Sep 24, 2024 by Dow Jones
Sep 10, 2024
Arcus Biosciences Announces New Employment Inducement Grants, from 4:35PM ET on Tuesday Sep 10, 2024 by Dow Jones
4:35PM ET on Tuesday Sep 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Arcus Biosciences Inc | 1.4B | -5.0x | --- |
Ardelyx Inc | 1.5B | -25.0x | --- |
Gyre Therapeutics Inc | 1.2B | -14.7x | --- |
Nurix Therapeutics Inc | 1.5B | -8.0x | --- |
Xencor Inc | 1.4B | -7.1x | --- |
Immatics NV | 1.2B | -12.6x | --- |
Company Information
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Contact Information
- Headquarters
- 3928 Point Eden WayHAYWARD, CA, United States 94545-3719
- Phone
- 510-694-6200
- Fax
- 302-730-1370
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Terry Rosen
- President, Co-Founder
- Juan Jaen
- Chief Financial Officer
- Robert Goeltz
- Chief Operating Officer
- Jennifer Jarrett
- General Counsel
- Carolyn Tang
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $247.0M |
Shares Outstanding | 91.4M |
Arcus Biosciences Inc does not pay a dividend. | |
Beta | 0.88 |
EPS | $-3.10 |
Book Value | $6.12 |
P/E Ratio | -5.0x |
Price/Sales (TTM) | 5.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -118.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
